Karyopharm Therapeutics (KPTI) EBITDA Margin (2012 - 2026)

Karyopharm Therapeutics (KPTI) has reported EBITDA Margin for 15 consecutive years, with 67.38% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA Margin fell 308.0% year-over-year to 67.38%; the trailing twelve-month figure through Jun 2026 stood at 53.5% (up 3043.0% YoY), and the FY2025 full-year result was 62.1%, up 2014.0% from the prior year.
• EBITDA Margin declined to 67.38% in Q2 2026 per KPTI's latest filing, from 52.36% in the prior quarter.
• Across five years, EBITDA Margin topped out at 34.56% in Q3 2025 and bottomed at 112.03% in Q4 2023.
• Historically, EBITDA Margin has averaged 81.85% across 5 years, with a median of 79.85% in 2023.
• The widest YoY moves for EBITDA Margin: up 15261 bps in 2022, down 13805 bps in 2022.
• Over 5 years, EBITDA Margin stood at 100.86% in 2022, then dropped by 11 bps to 112.03% in 2023, then advanced by 9 bps to 102.42% in 2024, then jumped by 49 bps to 52.36% in 2025, then slipped by 29 bps to 67.38% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 67.38%, 52.36%, and 34.56% for Q2 2026, Q4 2025, and Q3 2025 respectively.